GH Research Announces Pricing of $117.5 Million Underwritten Offering | GH Research
TL;DR
DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the pricing of an underwritten offering in the United
These entries start auto-generated and improve with human input. Your contributions help!
Published Undated · Added Apr 30, 2026